Quick response to rituximab in a patient with Ro52-Jo1 complex-associated antisynthetase syndrome debuting with rapidly progressive interstitial lung disease and diffuse alveolar haemorrhage

Esteban-Vazquez, Ana; Cobo-Ibanez, Tatiana; Mora, Gema; Vidal, Martha; Bayon-Garcia, Cristina; Munoz-Fernandez, Santiago.
Rev. patol. respir ; 26(3): 76-79, jul.- sept. 2023. ilus
Artículo en Inglés | IBECS (España) | ID: ibc-226105

Documentos relacionados

  1. Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center.
  2. Development of a novel, highly sensitive assay for quantification of minimal residual B cells in autoimmune disease and comparison to traditional methods across B-cell-depleting agents.
  3. Pre-Infusion Checklist For Rituximab In Pemphigus Vulgaris Patients: Clinical Audit.
  4. Improved survival for dose-intensive chemotherapy in primary mediastinal B-cell lymphoma: a systematic review and meta-analysis of 4,068 patients.
  5. Rituximab treatment for multiple sclerosis.
  6. [Expert consensus on the application of rituximab in the treatment of membranous nephropathy].
  7. Rituximab for eradicating inhibitors in people with acquired haemophilia A.
  8. Rituximab treatment in resistant lupus nephritis: A single-center prospective study.
  9. Gefitinib induced Pemphigus Vulgaris with PRIDE complex.
  10. Current understandings in treating children with steroid-resistant nephrotic syndrome.